• Je něco špatně v tomto záznamu ?

Personalized ex vivo multiple peptide enrichment and detection of T cells reactive to multiple tumor-associated antigens in prostate cancer patients

P. Taborska, D. Stakheev, Z. Strizova, K. Vavrova, M. Podrazil, J. Bartunkova, D. Smrz,

. 2017 ; 34 (10) : 173. [pub] 20170902

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024685

Grantová podpora
NV16-28135A MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Článek

E-zdroje Online Plný text

NLK ProQuest Central od 1997-03-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2013-03-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-03-01 do Před 1 rokem

Personalized peptide vaccination is a promising immunotherapeutic approach in prostate cancer (PCa). We therefore examined whether an approach, utilizing personalized multiple peptide-mediated ex vivo enrichment with effector T cells reactive to multiple tumor-associated antigens (TAAs), could be employed as a basis for the development of T cell immunotherapy of PCa. In this study, we used the non-adherent fraction (lymphocytes) of cryopreserved peripheral blood mononuclear cells from a leukapheretic product of biochemically recurrent (BR, n = 14) and metastatic hormone-refractory (HR, n = 12) PCa patients. The lymphocytes were primed with a pool of mixed overlapping peptides derived from 6 PCa TAAs-PSA, PAP, NY-ESO-1, MAGE-A1, MAGE-A3 and MAGE-A4. After 2 weeks of culture, the cells were stimulated with the peptides and T cell reactivity determined by externalization of CD107a. No TAAs-reactive effector T cells were detected in the patient's lymphocytes after their reconstitution. However, following their priming with the TAAs-derived peptides and 2-week culturing, the lymphocytes became enriched with polyclonal TAAs-reactive effector CD8+ T cells in 8 out of 14 BR and 5 out of 12 HR patients. No such reactive CD8+ T cells were detected in cultured lymphocytes without the peptide priming. Stimulation of the responding cultures with peptides derived from individual TAAs revealed a unique repertoire of the reactive CD8+ T cells. Our strategy revealed that the personalized multiple peptide-mediated ex vivo enrichment with multiple TAAs-reactive T cells in the PCa patient's lymphocytes is a viable approach for development of T cell immunotherapy of PCa.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024685
003      
CZ-PrNML
005      
20180717101926.0
007      
ta
008      
180709s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12032-017-1035-x $2 doi
035    __
$a (PubMed)28866803
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Taborska, Pavla $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, V Uvalu 84, 150 06, Prague 5, Czech Republic.
245    10
$a Personalized ex vivo multiple peptide enrichment and detection of T cells reactive to multiple tumor-associated antigens in prostate cancer patients / $c P. Taborska, D. Stakheev, Z. Strizova, K. Vavrova, M. Podrazil, J. Bartunkova, D. Smrz,
520    9_
$a Personalized peptide vaccination is a promising immunotherapeutic approach in prostate cancer (PCa). We therefore examined whether an approach, utilizing personalized multiple peptide-mediated ex vivo enrichment with effector T cells reactive to multiple tumor-associated antigens (TAAs), could be employed as a basis for the development of T cell immunotherapy of PCa. In this study, we used the non-adherent fraction (lymphocytes) of cryopreserved peripheral blood mononuclear cells from a leukapheretic product of biochemically recurrent (BR, n = 14) and metastatic hormone-refractory (HR, n = 12) PCa patients. The lymphocytes were primed with a pool of mixed overlapping peptides derived from 6 PCa TAAs-PSA, PAP, NY-ESO-1, MAGE-A1, MAGE-A3 and MAGE-A4. After 2 weeks of culture, the cells were stimulated with the peptides and T cell reactivity determined by externalization of CD107a. No TAAs-reactive effector T cells were detected in the patient's lymphocytes after their reconstitution. However, following their priming with the TAAs-derived peptides and 2-week culturing, the lymphocytes became enriched with polyclonal TAAs-reactive effector CD8+ T cells in 8 out of 14 BR and 5 out of 12 HR patients. No such reactive CD8+ T cells were detected in cultured lymphocytes without the peptide priming. Stimulation of the responding cultures with peptides derived from individual TAAs revealed a unique repertoire of the reactive CD8+ T cells. Our strategy revealed that the personalized multiple peptide-mediated ex vivo enrichment with multiple TAAs-reactive T cells in the PCa patient's lymphocytes is a viable approach for development of T cell immunotherapy of PCa.
650    _2
$a senioři $7 D000368
650    _2
$a antigeny nádorové $x imunologie $7 D000951
650    _2
$a CD8-pozitivní T-lymfocyty $x imunologie $7 D018414
650    _2
$a kultivované buňky $7 D002478
650    _2
$a lidé $7 D006801
650    _2
$a imunoterapie $x metody $7 D007167
650    _2
$a kalikreiny $x imunologie $7 D007610
650    _2
$a leukocyty mononukleární $x imunologie $7 D007963
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melanomové antigeny $x imunologie $7 D058950
650    _2
$a membránové proteiny $x imunologie $7 D008565
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádorové proteiny $x imunologie $7 D009363
650    _2
$a peptidy $x imunologie $7 D010455
650    _2
$a individualizovaná medicína $x metody $7 D057285
650    _2
$a prostatický specifický antigen $x imunologie $7 D017430
650    _2
$a nádory prostaty $x imunologie $x patologie $7 D011471
650    _2
$a T-lymfocyty $x imunologie $7 D013601
655    _2
$a časopisecké články $7 D016428
700    1_
$a Stakheev, Dmitry $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, V Uvalu 84, 150 06, Prague 5, Czech Republic.
700    1_
$a Strizova, Zuzana $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, V Uvalu 84, 150 06, Prague 5, Czech Republic.
700    1_
$a Vavrova, Katerina $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, V Uvalu 84, 150 06, Prague 5, Czech Republic.
700    1_
$a Podrazil, Michal $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, V Uvalu 84, 150 06, Prague 5, Czech Republic.
700    1_
$a Bartunkova, Jirina $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, V Uvalu 84, 150 06, Prague 5, Czech Republic.
700    1_
$a Smrz, Daniel $u Institute of Immunology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, V Uvalu 84, 150 06, Prague 5, Czech Republic. daniel.smrz@lfmotol.cuni.cz.
773    0_
$w MED00012126 $t Medical oncology (Northwood, London, England) $x 1559-131X $g Roč. 34, č. 10 (2017), s. 173
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28866803 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180717102225 $b ABA008
999    __
$a ok $b bmc $g 1316816 $s 1021606
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 34 $c 10 $d 173 $e 20170902 $i 1559-131X $m Medical oncology $n Med Oncol $x MED00012126
GRA    __
$a NV16-28135A $p MZ0
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace